Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology

Recruiting now · Not applicable

Conditions studied: Oncologic Disease, Hematologic Diseases

In brief

Currently, the molecular characterization of onco-hematological, onco-immunological and hematological diseases, at onset or in relapse, of patients with suspected diagnosis afferent to the CROP centers, is done through centralization of biological samples at reference laboratories outside the Tuscany Region. In order to preserve the wealth of clinical and biological data and use it for the benefit of present and future patients treated at the CROP centers, it is useful to evaluate the feasibility of centralization and molecular typing of mutations present in tumor tissue at the IRCCS AOU Meyer Oncohematology Laboratories and subsequently the analysis of clinical data from patients with diseases not under study to lay the foundations of a translational database that can then be associated with a biobank in the future. This will enable a targeted contribution to pediatric oncohematology research, investing in possible targeted therapies with those patient subgroups that benefit from personalized disease assessment in mind. The goal of the project is to improve the regional infrastructure dedicated to organized data collection and management of biological samples in adequate time resulting in better and more comprehensive data collection.

Key facts

Study ID

NCT06304194

Run by

Meyer Children's Hospital IRCCS

People needed

340

Starts

2023-07-05

Expected to finish

2028-07-05

Last updated by the study team

2024-03-12

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnostic suspicion of oncologic, hematologic or onco-immunologic disease
• Suspected recurrence of oncological, onco-hematological, hematological or onco -immunological disease
• Availability of biological material
• Signature of informed consent
• Age between 0 and 30 years

You may not qualify if…

• Failure to sign the consent
• Insufficiency of biological material for analysis
• Patients with HIV, HCV and HBV seropositivity (HBSAg) due to biohazard and bias related to patients' immunological status that could influence gene expression and tumor behavior.

Where it is running

• Meyer Children's Hospital IRCCS — Florence, Italy (enrolling)
• Azienda Ospedaliero-Universitaria Pisana — Pisa, Italy (enrolling)
• Azienda Ospedaliero-Universitaria Senese — Siena, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.